Compare prices and buy Vilon from 1 research peptide vendor - also called suppliers or sources. Updated daily.
A synthetic dipeptide (Lys-Glu / KE, CAS 45234-02-4) in the Khavinson short-peptide family, associated with thymus and immune tissue. Reported in Russian rodent studies to extend lifespan and reduce the incidence of spontaneous tumors. Part of the Cytogen class. It has no FDA approval.
For research purposes only. Not medical advice.
Vilon is a synthetic dipeptide, Lys-Glu (lysine joined to glutamic acid, written KE), from Vladimir Khavinson's short-peptide program at the Saint Petersburg Institute of Bioregulation and Gerontology. In Longevity and Bioregulators, it and Crystagen are the immune and thymic entries. FDA's substance registry, GSRS, files it as lysylglutamic acid, lists Vilon among its names and gives CAS 45234-02-4 and the formula C11H21N3O5, a molecular weight of about 275.
A 1997 review by Vyacheslav Morozov and Khavinson in the International Journal of Immunopharmacology introduces Vilon as a novel immunomodulatory dipeptide the group synthesized, after describing the calf thymus extract Thymalin and Thymogen, a drug built on a dipeptide isolated from it. The Thymalin page covers the paper that names Lys-Glu among the extract's components.
The group's own reviews assign it to the immune system. A 2021 table in Molecules lists KE, Vilon, for regulation of immune system function, alongside antioxidant, stress-protective and geroprotective effects, neuronal differentiation of stem cells, differentiation of plant cells and DNA binding. A 2022 table in the International Journal of Molecular Sciences lists it as an immunoprotector.
The studies behind that label are cell and animal work from Khavinson's institute and its collaborators:
The family's proposed mechanism is direct DNA binding. The developers' 2021 review reports that in a 2019 computer docking screen of all dipeptides, KE had the best binding parameters to the DNA sequence TCGA among those with free ends.
These are animal data, and Khavinson is an author on each paper.
A 2000 paper in Bulletin of Experimental Biology and Medicine studied female CBA mice treated from the sixth month of life. Its abstract reports that Vilon increased physical activity and endurance, lowered body temperature, prolonged lifespan and prevented the development of spontaneous tumors, with no effect on age-related changes in estrous function or free radical processes (Khavinson, 2000). The abstract gives no figures, and PeptideScouter could not read the full text.
A 2001 paper in Mechanisms of Ageing and Development compared Lys-Glu with the pineal tetrapeptide Epitalon in female CBA mice from six months of age until natural death. Its abstract reports that Lys-Glu increased physical activity, followed by fewer spontaneous lung adenomas, and reports gains in survival for the pineal peptide only (Anisimov, 2001).
A 2002 study in female transgenic FVB mice carrying the HER-2/neu (erbB-2) oncogene concluded that Epitalon inhibited breast-tumor development. For Vilon, its abstract reports two or more tumors per mouse in 95% of animals against 75% of controls (Alimova, Voprosy Onkologii, 2002, in Russian).
The human reports PeptideScouter found are Russian-language papers, and ClinicalTrials.gov lists no study under the name Vilon or the sequence Lys-Glu. Two papers in Advances in Gerontology (Kuznik, 2006 and 2007) describe adding Vilon to the treatment of patients with type 1 diabetes and report higher levels of the natural anticoagulants antithrombin III and protein C, stronger fibrinolysis and shifts in lymphocyte subsets. Their abstracts give no patient numbers.
PeptideScouter found no US approval or compounding record for Vilon. As of October 22, 2026, it appears in none of these:
The GSRS record described above is a substance identifier, and it implies no approval.
Its developers reported so in mice. A 2000 paper in Bulletin of Experimental Biology and Medicine by Vladimir Khavinson and colleagues reports that Vilon, the dipeptide Lys-Glu, given to female CBA mice from the sixth month of life prolonged lifespan and prevented the development of spontaneous tumors. Its abstract gives no figures. A 2001 paper in Mechanisms of Ageing and Development from the same group, also in female CBA mice, reports for Lys-Glu increased physical activity followed by fewer spontaneous lung adenomas, and reports survival gains only for the pineal peptide it was compared with. These are animal results from the developers' own group.
Because its developers assign it there. A 1997 review by Vyacheslav Morozov and Vladimir Khavinson introduced Vilon as a novel immunomodulatory dipeptide, in the same research line as the calf thymus extract Thymalin. The group's later reviews list the dipeptide Lys-Glu under regulation of immune system function (2021) and as an immunoprotector (2022). In a 2002 study in mouse thymocytes it had the strongest comitogenic effect on proliferation of the three short peptides tested. The supporting work is cell and animal research from the developers' institute and its collaborators.
All three come from Vladimir Khavinson's thymic-peptide program, but they are different products. Thymalin is an extract of calf thymus, a mixture of peptides, and its developers' 2021 review describes the dipeptide Lys-Glu as part of it. Vilon is synthetic Lys-Glu. Thymogen is a different dipeptide, Glu-Trp, which its developers isolated from Thymalin and then synthesized.
Only in Russian-language studies, and ClinicalTrials.gov lists no study of it as of October 2026. Two Russian-language papers from 2006 and 2007 describe adding Vilon, the dipeptide Lys-Glu, to the treatment of patients with type 1 diabetes and report higher levels of the natural anticoagulants antithrombin III and protein C and shifts in lymphocyte subsets. Their abstracts give no patient numbers. The lifespan and tumor findings associated with Vilon come from mouse studies.
PeptideScouter found no US approval or compounding record for it. As of October 22, 2026, Vilon does not appear in Drugs@FDA, in either table of FDA's Category 2 list of bulk drug substances raising significant safety risks, in FDA's lists of substances nominated for compounding under Sections 503A and 503B, or among the substances FDA named for its July 2026 and next Pharmacy Compounding Advisory Committee meetings, and no FDA warning letter names it. FDA's substance registry, GSRS, holds an identifier record for the dipeptide as lysylglutamic acid, which is not an approval.
Vilon is sold by 1 research peptide vendor indexed on PeptideScouter, with 1 tracked listing compared per vendor in the table above. Pricing is normalized and refreshed daily.
All 1 indexed research peptide vendor currently have Vilon in stock. Stock state is refreshed daily from each vendor's catalog.
Platinum Lion Peptides currently lists Vilon at $3.25/mg, the lowest listed price across 1 tracked research peptide vendor. With current vendor discount codes applied, the lowest effective price is $2.92/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 1 vendor listing Vilon publish a PeptideScouter code, worth 10% off. Applied, the lowest effective price falls from $3.25/mg listed to $2.92/mg at Platinum Lion Peptides. Each vendor's code is shown beside its price in the table above.
1 research peptide vendor currently lists Vilon on PeptideScouter. We track 1 listing across size and kit variants.
Vilon's CAS Registry Number is 45234-02-4.
